Clinical trial · Observational
Identification of Patients With Age-Related Clonal Hematopoiesis (ARCH) Among Cancer Survivors
Identification of Patients With Age-Related Clonal Hematopoiesis (ARCH) Among Cancer Survivors.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to see if patients with cancer have a certain amount of genetic mutations in their blood. If certain levels of mutations are found in specific genes, patients may have a condition known as ARCH. The prevalence of ARCH is higher in cancer patients who received prior chemotherapy or radiation. Studying ARCH from your blood samples may also help researchers predict which patients are more likely to be prone to heart disease. Patients who are about to start chemotherapy/radiation, and patients who have completed chemotherapy/radiation will be approached to measure the incidence of ARCH. 5-10mL blood samples will be collected before and after treatment, and if ARCH is detected in a laboratory analysis, another blood sample will be collected. Patients with ARCH will repeat the blood collection yearly, and also be referred to a cardiology clinic for follow up.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Monitoring of ARCH variants | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Referral to cardiology clinic
- timeFrame
- 6-12 months
Secondary outcomes (1)
- measure
- The incidence of ARCH stratified by tumor type.
- timeFrame
- 6-12 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 60 Years
Show eligibility criteria text
* Age ≥ 60 * Completed chemotherapy and/or radiation therapy and are being followed at Princess Margaret Cancer Centre i) Patient must be in remission for \> 3 months after completing chemotherapy or radiation ii) Predicted 5 year survival of \>75% iii) Peripheral blood counts must have returned to normal as defined by: 1. Platelets ≥ 100 x 109/L 2. PMN ≥ 1 x 109/L Or * Prior to chemotherapy and/or radiation therapy at the Princess Margaret Cancer Centre. * All histologically/cytologically proven tumour types (solid tumours and hematologic malignancies) will be eligible. * Received or will receive regimens of chemotherapy or radiation with doses expected to produce transient myelosuppression (PMN\<0.5x109/L) in at least 80% of treated patients (The identification and definition of appropriate myelosuppressive chemotherapy and radiation regimens will be at the discretion of the treating physician and will vary among disease sites). * Patients must have the ability to understand the requirements of the study and provide written informed consent, which includes authorization for release of protected health information * Patient must be willing to provide a peripheral blood sample. Exclusion Criteria: * Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.
References
Publications (0)
Data not yet available